A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|12|1625-1634

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.12, 2012-04, pp. : 1625-1634

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists

By  

Current Drug Targets, Vol. 11, Iss. 3, 2010-03 ,pp. : 380-391

Bentham Science Publishers

Access to resources Recommend Favorite

Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1805-1812

Bentham Science Publishers

Access to resources Recommend Favorite

Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal

By  

Current Drug Targets, Vol. 14, Iss. 8, 2013-01 ,pp. : 880-888

Bentham Science Publishers

Access to resources Recommend Favorite

P2Y 12 ADP receptor antagonists after percutaneous coronary interventions P2Y 12 -ADP-Rezeptorantagonisten nach perkutanen Koronarinterventionen

By Trenk Dietmar  

PHARMAKON, Vol. 1, Iss. 1, 2013-01 ,pp. : 53-60

Govi-Verlag

Access to resources Recommend Favorite

P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis

By  

Current Pharmaceutical Design, Vol. 22, Iss. 29, 2016-09 ,pp. : 4568-4576

Bentham Science Publishers

Access to resources Recommend Favorite